Introduction
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is standard therapy in patients with acute coronary syndromes (ACS) and in those undergoing drug-eluting stent (DES) implantation, although the obligate duration of DAPT continues to be debated. 1 In this regard, the extent to which the net benefit of different DAPT durations may vary according to clinical presentation is still controversial. Patients with ACS have increased rates of recurrent ischaemic events compared with those with stable coronary artery disease (CAD), 2 and therefore, ACS patients may be more likely to benefit from prolonged DAPT. However, data on optimal DAPT duration are relatively scant and controversial even in ACS patients, warranting further investigation. 1 As many studies have challenged the notion that 1-year DAPT is necessary after DES placement, we performed an individual patient data (IPD) meta-analysis of RCTs investigating the safety and efficacy of shortening DAPT to <1 year after DES implantation in patients with and without ACS.
Methods

Study design and selection
For this meta-analysis, we included RCTs enrolling patients with stable CAD or ACS undergoing DES implantation and randomized to a short duration of DAPT (3-6 months) versus a longer duration (> _1 year), censoring data at 1 year. RCTs comparing 1-year vs. >1-year DAPT, or enrolling patients not treated with DES were excluded. These criteria were applied at the study level. Relevant RCTs were searched in August 2015 through MEDLINE, the Cochrane database, the EMBASE database, www. tctmd.com, www.clinicaltrials.gov, www.clinicaltrialresults.org, www.cardi osource.com, abstracts, and presentations from major cardiovascular meetings, using the keywords randomized clinical trial, drug-eluting stent, dual antiplatelet therapy, clopidogrel, aspirin, and thienopyridines. Two investigators (TP and DDR) independently reviewed the titles, abstracts, and studies to determine whether they met the inclusion criteria. Risk of bias was assessed using the Cochrane method. Further methodological details of the meta-analysis are provided in the Supplemental Material. The reporting of the study was in compliance with the PRISMA IPD statement. 3 
Endpoints and definitions
The primary objective was to investigate whether there is an interaction between DAPT duration and clinical presentation for the composite risk of 1-year myocardial infarction (MI) or definite/probable stent thrombosis (ST). Secondary pre-specified endpoints included the 1-year rates of all-cause, cardiac and non-cardiac death, MI, ST, stroke, target vessel revascularization (TVR), major bleeding, any bleeding, and various combinations of these endpoints. The endpoint definitions as applied in each trial were incorporated. Patient-level data were obtained from the principal investigators of the trials meeting the inclusion criteria and combined in a single pooled database. Interaction analyses between DAPT duration and clinical presentation were performed using frequentist IPD pairwise meta-analysis. Network meta-analysis was performed to compare outcomes of 3-month vs. 6-month vs 1-year DAPT separately in ACS and non-ACS patients.
To minimize bias by including events in the early period, landmark analyses were performed at the time of DAPT discontinuation in the short-DAPT treatment group. For this analysis, patients with ischaemic or bleeding events occurring before the landmark time-point, or those not compliant with the original randomization assignment were excluded, resulting in a 'per-protocol' population.
Statistical analysis
Continuous variables are displayed as means and standard deviation (SD) and were compared using two-way ANOVA stratified by trial. Categorical variables are displayed as counts and percentages and were compared with a logistic regression analysis stratified by trial. IPD metaanalysis was performed using a one-stage approach. Patient data were combined in a single dataset and fitted in a Cox regression model stratified by trial. The proportional assumptions were verified using Schoenfeld residuals. Results are reported as hazard ratio (HR) with 95% confidence interval (CI). A simple Cox regression model was used to generate cumulative hazard function curves of events for each outcome of interest. Kaplan-Meier estimates were also determined. As sensitivity analyses, we investigated the relative risk and benefit of short DAPT versus prolonged DAPT using standard parametric survival models, as well as Royston Parmar models. 4 For Royston-Parmar models we evaluated 1, 2, and 3 knots of the spline function.
For the network meta-analysis treatment effect estimates for short vs. long DAPT were obtained as log HR and standard error from individual RCTs. 5 These estimates were then used to obtain head-to-head comparison estimates between different DAPT regimens (3-months vs 6-months vs 1-year). A frequentist framework based on graph-theoretical method was used to calculate point estimates with 95% CI using a random-effects model (R netmeta package). 6 Pair-wise inconsistency was assessed with the I2 statistic. P values <0.05 were considered significant. Statistical analyses were performed using Stata 12 SE (StataCorp, College Station, Texas) and R 3.2.3 (R Foundation for Statistical Computing, Vienna, Austria).
Results
As shown in Supplementary material online, Figure S1 , of 1042 potentially relevant studies, seven trials met the inclusion criteria. Data were obtained for six of them and were included in the final meta-analysis. [7] [8] [9] [10] [11] [12] The major characteristics of the included trials are shown in Supplementary material online, Table S1 , the inclusion and exclusion criteria are reported in Supplementary material online, Table S2 , the risk of bias in Supplementary material online, Table S3 , the definitions of clinical endpoints in Supplementary material online, Table S4 , and the clinical angiographic and procedural characteristics stratified by DAPT duration in Supplementary material online, 
Clinical outcomes in the intention-totreat population
At 1-year follow up, patients with ACS compared with stable CAD had significantly higher composite rates of MI or definite/probable ST (HR = 1.50, 95%CI 1.12-2.00; P = 0.006), and cardiac death, MI, or definite/probable ST, but similar rates of major bleeding.
In the entire study population < _6-month DAPT was associated with similar rates of composite MI or definite/probable ST compared with 1-year DAPT (HR 1.15, 95%CI 0.88-1.51; P = 0.31) with a borderline interaction between DAPT duration and clinical presentation (P interaction = 0.09) ( Table 1 Table 1 and Figure 2 . Of note, all-cause mortality was not significantly different with short vs. long DAPT in both patients with stable CAD and ACS. Similar results were apparent in sensitivity analyses using parametric survival models as well as Royston Parmar models (Supplementary material online, Table S9 ).
Landmark analysis in the per-protocol population
The per protocol population included 11 070 patients, including 4567 (41.3%) with ACS and 6502 (58.7%) with stable CAD. Their baseline characteristics stratified by DAPT duration are presented in Supplementary material online, Tables S10-12. For the entire randomized per-protocol population beginning after the time-point of DAPT discontinuation, short DAPT was associated with similar rates of composite MI or ST as prolonged DAPT (HR 1.02, 95%CI 0. 67- 1.56 , P = 0.77), with a borderline interaction favoring prolonged DAPT in ACS but not stable CAD (P interaction = 0.07) (Supplementary material online, Table S13 and Figure 3 ). Significant interactions between DAPT duration and clinical presentation were present for MI and TVR, with prolonged DAPT favored in ACS patients and shorter DAPT favoured in stable CAD patients. Conversely, < _6-month DAPT was associated with lower 1-year rates of major bleeding (HR 0.32, 95%CI 0.14-0.70; P = 0.005) and any bleeding (HR 0.48, 95%CI 0.30-0.79, P = 0.004) compared with prolonged DAPT, with no interaction between DAPT duration and clinical presentation (Supplementary material online, Table S13 ). Finally, patients treated with short vs. long DAPT had a trend toward lower rates of noncardiac mortality (HR 0.62, 95%CI 0.38-1.01; P = 0.058), with a non-significant interaction between DAPT duration and clinical presentation (P interaction = 0.08).
Three-months vs. six-months vs. Twelvemonths of Dual antiplatelet therapy
The evidence network is shown in Supplementary material online, Figure S2 and the results in Figure 4 . All trials included in the metaanalysis were sufficiently similar in all respects other than the treatment assignment, holding the transitivity assumption of network meta-analysis. Compared with ACS patients treated with 12-month DAPT, those treated with 3-month DAPT (HR 2.08, 95%CI 1.10-3. 93) but not 6-month DAPT (HR 1.28, 95%CI 0.73-2.27) had higher composite MI or ST rates. Conversely, there was no significant difference in the risk of MI or ST in stable patients treated with 3-month, 6-month, or 12-month DAPT. Finally, treatment with 3-month and 6-month DAPT was associated with lower rates of major bleeding and any bleeding compared with 12-month DAPT, independent of clinical presentation.
Additional analyses
A significant interaction was apparent between DAPT duration, clinical presentation and history of prior MI, such that 1-year DAPT significantly reduced the risk of MI or ST compared with short DAPT only in patients with ACS and a history of prior MI, whereas no significant difference between the two DAPT strategies was apparent in the other clinical strata (Supplementary material online, Table S14 ). No statistical heterogeneity was present in any pair-wise analyses for the main outcome measures (Supplementary material online, Table  S15 ).
Discussion
The principal findings of the present patient-level pooled metaanalysis including six RCTs and 11 473 patients are: (1) Overall, a strategy of short-term DAPT (3 or 6 months) after DES implantation is associated with similar 1-year composite rates of MI or definite/ probable ST compared with 1-year DAPT, with a borderline interaction between DAPT duration and clinical presentation; (2) Similar results were seen in the per-protocol population in the landmark period between DAPT discontinuation and 1-year follow-up; (3) In patients with ACS, 3-month but not 6-month DAPT was associated with higher rates of MI or ST compared with 1-year DAPT, whereas in stable CAD no such difference was apparent; (4) Patients with both ACS and stable CAD treated with short DAPT (either 3 or 6 months) had lower rates of bleeding compared with patients treated with 1-year DAPT; and (5) Although by intention-to-treat all-cause mortality was not significantly different with short vs. long DAPT, a trend towards increased non-cardiac mortality with prolonged compared with short DAPT was present in the per-protocol landmark period between DAPT discontinuation and 1-year follow-up, with no interaction present between DAPT duration and clinical presentation in either analysis. Several RCTs have recently challenged the notion that 1-year (or longer) DAPT is necessary after contemporary DES implantation, suggesting that 6-month or even 3-month DAPT may be as effective and safer. [7] [8] [9] [10] [11] [12] [13] In stable CAD, European and US guidelines state 6-month DAPT may be reasonable after second generation DES in stable CAD. 14, 15 The optimal DAPT duration in patients with ACS is also controversial. There is general consensus that in such patients DAPT should be administered for at least1 year, 16 but the evidence supporting this recommendation relies on a single randomized trial (CURE) performed nearly 2 decades ago when ACS patients were treated conservatively, and before DES. 17 In this regard, second generation DES may be less thrombogenic than bare metal stents. 18 In CURE, a reduction in the risk of cardiovascular death, MI or stroke favoring DAPT with clopidogrel compared with aspirin monotherapy was already apparent at 30 days, confounding interpretation of the utility of DAPT thereafter. Unfortunately, a second randomization at a later time period was not performed, which might have addressed this issue. Moreover, landmark analysis from CURE demonstrated that nearly all of the benefit of DAPT occurred within 3 months after randomization. 19 Specifically, DAPT compared with aspirin monotherapy prevented 20 cardiovascular events/1000 patients treated during the first 3 months, vs. only two initial cardiovascular events/ 1000 patients treated between 3 and 12 months. In addition, among 2658 patients undergoing PCI, no significant difference in any ischaemic endpoint was apparent between aspirin monotherapy versus DAPT in a landmark period between 1 month and 1 year. 20 In the present patient-level pooled meta-analysis including 11 473 patients, 4758 of whom had ACS, we found no significant difference in the risk of MI or definite/probable stent thrombosis between < _6-month DAPT versus 1-year DAPT in the entire randomized population. However, a trend was apparent suggesting a significant benefit of 1-year DAPT vs. shorter DAPT in ACS patients, and by network meta-analysis 3-month DAPT, but not 6-month DAPT was associated with significantly higher rates of MI or ST in ACS. In contrast, no significant difference in the risk of MI or ST was apparent in patients with stable CAD treated with 3, 6, or 12 months DAPT.
These findings contrast with the DAPT trial, which suggested higher rates of ST and MI in patients treated with 1-year DAPT compared with 2.5-year DAPT after DES, irrespective of clinical presentation. 21, 22 The difference in DAPT duration between treatment arms was 18 months in the DAPT trial, but only 6-9 months in our metaanalysis. It is possible that a benefit may appear with DAPT continuation longer than 1 year. Moreover, in the DAPT trial, the benefit of prolonged DAPT was accentuated in patients with MI at presentation, 22 consistent with the results of the present study. Our analysis confirms that prolonging DAPT carries a substantial risk of major bleeding and any bleeding. These findings are of clinical relevance considering the association between bleeding and mortality. 23 In addition, a meta-regression analysis including eight RCTs has recently found a significant association between all bleeding and noncardiovascular mortality, but not between ST and cardiovascular mortality, suggesting that these endpoints may weigh differently on the risk of mortality. 24 In this regard, we observed a borderline increase in non-cardiac mortality with prolonged DAPT compared with aspirin monotherapy in the landmark period between DAPT discontinuation and 1-year. These data suggest that the optimal DAPT duration after DES placement should be tailored in individual patients after carefully balancing the risks of ischaemic versus bleeding events. The DAPT score was developed to identify patients with a greater risk of ischemia than bleeding who may benefit the most from prolonging DAPT. 21 Limitations of this score include its modest discrimination power, absence of ticagrelor treatment, applicability only to the 12-30-month period after DES, and lack of availability of several important variables predicting bleeding. 22 The DAPT score also needs external validation in a trial of different DAPT durations using contemporary DES.
Further studies are thus warranted to investigate the utility of the DAPT score. The majority of enrolled patients with ACS were biomarker negative, and few had acute STEMI, representing a relatively low-risk cohort. However, 1-year DAPT significantly reduced the risk of MI or ST compared with short DAPT in patients with ACS and prior MI, whereas no significant difference was apparent in other clinical strata. These findings are consistent with the results of the PEGASUS trial, which showed significantly lower rates of ischaemic events with longterm DAPT with aspirin and ticagrelor compared with aspirin alone in patients with prior MI 1-3 years earlier, 25 and with a recent metaanalysis reporting benefit of long-term DAPT for secondary prevention in patients with previous MI. 26 Other limitations should be acknowledged. The analysis in patients with prior MI is underpowered and therefore should be interpreted with caution. A significant proportion of implanted DES was first generation devices, in particular fast-release zotarolimus-eluting stents, which are no longer used. However, as second generation DES are safer than first generation DES, 18 the balance between risk and benefit would likely favour shorter DAPT duration to an even greater degree with contemporary DES. Although we observed no significant difference in the risk of ischaemic events between 3-month versus 1-year DAPT in patients with stable CAD, further studies are required to establish the generalizability of this finding. All trials included in the meta-analysis were open-label, potentially introducing bias. Definitions of some clinical endpoints slightly differed across trials, potentially introducing effect modifiers. All patients were treated with clopidogrel as adjunctive therapy to aspirin. It remains undetermined how the more potent antiplatelet agents prasugrel and ticagrelor might affect the risk-benefit balance of prolonged DAPT in ACS.
Comparison between 3-month versus 6-month DAPT is based on indirect evidence only, and therefore should be interpreted with caution. Data from the large ISAR SAFE trial were not provided by the principal investigator, and therefore could not be included in the meta-analysis. 13 The lack of a significant difference in the risk of ischaemic endpoints between 6-month and 1-year DAPT in ACS patients should be interpreted with caution, given the low risk nature of these patients (67.0% unstable angina), and the trend toward greater ischaemic events with 6-month DAPT. Thus 1-year mandatory DAPT would be a prudent minimum in high-risk ACS patients. Considering the small number of studies included in the metaanalysis, we did not use common methods for evaluating publication bias such as Egger test or the funnel plot.
In conclusion, in the present meta-analysis including 11 473 patients treated with DES, the absolute and relative benefit of different DAPT durations varied according to clinical presentation. In patients with ACS, 3-month DAPT was associated with increased ischaemic risk, whereas 3-month DAPT appeared safe in stable CAD. Prolonged DAPT increases bleeding regarding of clinical presentation. Further study is required to identify the optimal duration of DAPT after DES in individual patients at varying level of ischaemic and bleeding risk.
